Company intelligence / Profile preview
Dadao Longda
Beijing, Beijing, Chinaddldbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Dadao Longda Biotechnology is a biopharmaceutical company dedicated to the development of innovative D-peptide drugs. The company utilizes a proprietary platform to engineer peptides composed of D-amino acids, which are designed to be more resistant to enzymatic degradation and less immunogenic than standard L-peptides. Their lead research programs focus on neurodegenerative conditions, specifically Alzheimer's disease, alongside efforts in oncology and metabolic health. Dadao Longda aims to bridge the gap between basic research and clinical application by advancing a pipeline of stable, high-affinity peptide therapeutics.
- Therapeutic areas
- OncologyNeurologyMetabolic Disorders
- Modalities
- PeptidesD-peptide therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Dadao Longda.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dadao Longda.